ALISON ELSHEIKH: Open Payments
NPI 1942841242 · AMSTERDAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$449 in 21 payments from 10 companies in 2025. Trend: 2023 $99 · 2024 $407 · 2025 $449
Food & beverage: $449
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $160 |
| AstraZeneca Pharmaceuticals LP | 3 | $68 |
| Lilly USA, LLC | 2 | $47 |
| Braeburn Inc. | 2 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| Indivior Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $25 |
| Novo Nordisk Inc | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Amgen Inc. | 1 | $14 |
Products named: VRAYLAR, AIRSUPRA, QULIPTA, BRIXADI, CRENESSITY, ZEPBOUND, SUBLOCADE, REXULTI.
Industry payments across NY — which companies pay providers there.
